Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening

Cystic Fibrosis Lung Disease Clinical Trial

— TRACK-CF  

Official title:

Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02270476
• Other study ID #: UKH-TRACK-1
• Status: Recruiting
• Start date: December 2011
• Est. completion date: December 2030

Study information

• Verified date: November 2023
• Source: Heidelberg University
• Contact: Marcus A Mall, MD
• Phone: +49 6221 56 4502
• Email: Marcus.Mall[@]med.uni-heidelberg.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to further characterize early CF lung disease in newborns, infants and toddlers with cystic fibrosis (CF).

Description:

Cystic fibrosis (CF) is the most common lethal genetic multisystem disease in Germany. Although life expectancy increased over the last decades, most of the CF patients die in young adulthood due to chronic CF lung disease with respiratory failure. CF lung disease is caused by a disturbed transport of salt and water by airway epithelia and dehydration of airway surfaces as a result of the underlying genetic defect in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gen. Up to now, no causal therapies for the majority of patients with CF are available. Little is known about onset and natural course as well as influencing factors of CF lung disease. Therefore, the first aim of this prospective, multicenter, uncontrolled, non-randomized, explorative longitudinal study is characterization of the onset and early course of CF lung disease. For this reason we will primarily include patients diagnosed by CF newborn screening (CF-NBS) or for any other reason in the first four months of life (early diagnosed, ED). In a second step we will compare data from these patients to those diagnosed clinically later in life (late diagnosed, LD). This will allow us to investigate the effect of early diagnosis and start of therapy. Starting at diagnosis, we will use data from annual routine check-ups (imaging like chest MRI, pulmonary function tests, microbiology from swabs and sputum, laboratory values, anthropometry) as well as data from a facultative, study-related bronchoscopy with lavage (microbiology, inflammation and immunology) for correlation with the course of CF lung disease (generation of hypotheses). Further study-related investigations are monthly telephone interviews on bronchopulmonary symptoms by a study nurse on the basis of a questionnaire and quarterly assessment of health-related quality of life on the basis of a validated questionnaire. We expect to gain a deeper insight into onset and early course of CF lung disease from the results of this study. So far, there is no trial that investigated the different aspects of CF lung disease (function, morphology, infectiology, inflammation) complementary in a longitudinal setting. We assume that knowledge on the natural history of CF lung disease in the vulnerable phase of early childhood has a great impact on the future development of new therapies (from symptomatic to causal). This shall lead to a further improvement in life expectancy and quality of life of patients with CF.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2030
• Est. primary completion date: December 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Newly diagnosed patients with Cystic Fibrosis (CF). Diagnosis of CF: at least one of the following three international accepted criteria is fulfilled: i) sweat chloride = 60mEq/L and/or ii) 2 CF-causing mutations in the CFTR gene and/or iii) changes typical for CF in the transepithelial potential difference in nasal or rectal epithelium.

2. Age and mode of diagnosis:

• Early diagnosed (ED): Initial diagnosis following CF-NBS or for other reasons in the first 4 months of life (in preterms corrected age of 4 months) after January 1st, 2006. Other reasons could be prenatal diagnostics, meconium ileus or positive family history.
• Late diagnosed (LD): Diagnosed after the fourth month of life due to clinical symptoms; initial diagnosis after January 1st, 2006. Exclusion Criteria: All patients are excluded who themselves or whose parents do not want to participate or that withdraw from the study; or those in whom the diagnosis of CF is unsure.

Further exclusion criteria are:

1. Preterms <30th week of gestation

2. Longer period of mechanical ventilation in first 3 months of life

3. A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol

4. Previous major surgery except for meconium ileus or atresia of the intestine

5. Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to CF

6. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator

7. Chronic lung disease other than CF (e.g. bronchopulmonary dysplasia)

8. History of adverse reaction to medication for sedation or known claustrophobia Criteria, which lead to a displacement of the procedures in sedation until the child has recovered: - Clinically significant upper airway obstruction as determined by investigator (e.g. severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea)

• Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy

Related Conditions & MeSH terms

• Cystic Fibrosis
• Cystic Fibrosis Lung Disease
• Fibrosis
• Lung Diseases
• Pulmonary Fibrosis

Locations

Country	Name	City	State
Germany	University Hospital Gießen and Marburg GmbH	Gießen	Hessen
Germany	Medizinische Hochschule Hannover	Hannover	Niedersachsen
Germany	University Children's Hospital Heidelberg, Cystic Fibrosis Centre	Heidelberg	Baden-Württemberg
Germany	University Children's Hospital Schleswig-Holstein	Lübeck	Schleswig-Holstein

Sponsors (2)

Lead Sponsor	Collaborator
Heidelberg University	German Center for Lung Research

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion with morphological and/or perfusion changes due to CF lung disease after chest MRI score in both groups		At age of 1, 2, 3, ...., 10 years of age
Primary	Proportion of patients with impairments in pulmonary function tests (e.g. multiple breath washout (MBW)) in both groups		At age of 1, 2, 3, ...., 10 years of age
Secondary	Rate of protocol-defined pulmonary exacerbations in both groups (ED vs. LD) that are necessitating an antibiotic therapy orally, intravenously or per inhalation		At age of 1, 2, 3, ...., 10 years of age
Secondary	Spontaneous development of infection or spectrum of pathogens, respectively, in throat and nose swabs as well as other airway secretions from routine diagnostics and if applicable bronchoalveolar lavage fluid (BALF)		At age of 1, 2, 3, ...., 10 years of age
Secondary	From the patients in whom PsA or other CF pathogens could not be isolated at the beginning of their participation, comparison of the portion of patients with a positive culture during participation in both groups (ED and LD)		At age of 1, 2, 3, ...., 10 years of age
Secondary	Time to first detection of a CF pathogen in both groups		At age of 1, 2, 3, ...., 10 years of age
Secondary	Time to first pulmonary exacerbation in both groups		At age of 1, 2, 3, ...., 10 years of age
Secondary	Portion of patients with increased biochemical inflammatory markers in both groups and magnitude of elevation		At age of 1, 2, 3, ...., 10 years of age
Secondary	Frequency of symptoms from monthly telephone interviews in both groups		At age of 1, 2, 3, ...., 10 years of age
Secondary	Health-related quality of life in both groups quarterly via Cystic Fibrosis Questionnaire (CFQ)		At age of 1, 2, 3, ...., 10 years of age
Secondary	Development of body weight, body height, ideal weight-for-height (IWFH), Body-Mass-Index (BMI), respiratory rate and oxygen saturation at room air in both groups		At age of 1, 2, 3, ...., 10 years of age
Secondary	Proportion with morphological changes due to CF lung disease after modified Chrispin-Norman Score for assessment of chest X-ray in both groups		At age of 1, 2, 3, ...., 10 years of age
Secondary	Magnitude and severity of alterations typical for CF by assessment with chest MRI and X-ray score in both groups		At age of 1, 2, 3, ...., 10 years of age
Secondary	Magnitude of impairment of pulmonary function test in both groups		At age of 1, 2, 3, ...., 10 years of age